TABLE 3.

The performance of these parameters for predicting CTRCD in derivation and validation cohort.

	C‐index (95% confidence interval)	p	p*	p**
Derivation cohort
Age + hypertension + previous cardiovascular disease	0.671 (0.588–0.812)	<0.001	0.85	0.43
HFA‐ICOS score	0.642 (0.454–0.716)	<0.001	0.081
Maximal apical FD (≥1.272)	0.688 (0.532–0.810)	<0.001
LVTFD‐based score	0.834 (0.701–0.932)
Validation cohort
Age + hypertension + previous cardiovascular disease	0.664 (0.503–0.761)	<0.001	0.80	0.37
HFA‐ICOS score	0.633 (0.416–0.705)	<0.001	0.084
Maximal apical FD (≥1.272)	0.679 (0.521–0.798)	<0.001
LVTFD‐based score	0.830 (0.698–0.925)

Note: LVTFD‐based score, the combination of age, hypertension, previous cardiovascular disease, and maximal apical FD by Cox model. p, LVTFD‐based score versus maximal apical FD or HFA‐ICOS score by Delong test; p*, maximal apical FD versus HFA‐ICOS score by Delong test; p**, HFA‐ICOS score versus age + hypertension + previous cardiovascular disease by Delong test.

Abbreviations: CTRCD, cancer therapy–related cardiac dysfunction; FD, fractal dimension; HFA‐ICOS, Heart Failure Association–International Cardio‐Oncology Society; LVTFD, left ventricular trabecular fractal dimension.